Bharat Parenter.
BSE: BPLPHARMA · Pharmaceuticals
Snapshot
Unlock Bharat Parenter.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bharat Parenterals Ltd. is a pharmaceutical company specialising in the manufacture of diverse formulations, including general medicines, B-Lactam, cephalosporins, anti-retroviral drugs, and veterinary products. Based in Vadodara, the company focuses on providing a broad spectrum of therapeutic solutions.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical formulations across human and veterinary health segments. It operates as a B2B and B2C manufacturer, leveraging its production facilities to serve domestic and potentially international markets.
- Founded:1992
Growth Outlook
Growth is expected to be driven by the expansion of its pharmaceutical product portfolio and the increasing demand for specialised formulations like anti-retrovirals. The company continues to leverage its established manufacturing infrastructure to capture market share in the competitive Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards imposed by health authorities, which could impact operations if non-compliance occurs.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can significantly affect profit margins.
- Market Competition. The pharmaceutical sector is highly fragmented and competitive, necessitating continuous investment in product development and cost efficiency.
- Pricing Controls. Government-mandated price caps on essential medicines may limit the company's ability to pass on cost increases to consumers.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Bharat Parenter. and 5,000+ companies — free.
Key Metrics
REVENUE
₹345 Cr
TTM · consolidated
NET PROFIT
₹27 Cr
TTM · consolidated
EPS
₹41.14
TTM · consolidated
RETURN ON EQUITY
8.3%
TTM · consolidated
P/E
33.0x
Q4 FY26 · consolidated
EV/EBITDA
14.7x
Q4 FY26 · consolidated
EBITDA MARGIN
21.2%
TTM · consolidated
NET PROFIT MARGIN
8.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bharat Parenter.BPLPHARMA | 689 | 33.00 | 14.73 | 9.4% | 21.2% | 8.3% | 9.0% | -16.7% |
Anuh PharmaANUHPHR | 713 | 16.26 | 12.03 | 16.7% | 8.6% | 12.3% | 16.3% | -21.7% |
Sigachi Indust.SIGACHI | 710 | -11.46 | 16.97 | -2.1% | 13.0% | -14.3% | -11.6% | -40.8% |
Themis MedicareTHEMISMED | 663 | 864.77 | 116.11 | -15.6% | 2.8% | 0.3% | -0.3% | -9.9% |
Shree Ganesh RemSGRL | 624 | 47.05 | 22.40 | — | 34.8% | 11.9% | 15.9% | +7.6% |
Anlon HealthcareAHCL | 605 | 1.97 | 13.92 | — | 26.3% | 13.3% | 20.9% | — |
As of Q4 FY26
Financials
Bharat Parenter.
BSE: BPLPHARMA · Pharmaceuticals
Snapshot
Unlock Bharat Parenter.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bharat Parenterals Ltd. is a pharmaceutical company specialising in the manufacture of diverse formulations, including general medicines, B-Lactam, cephalosporins, anti-retroviral drugs, and veterinary products. Based in Vadodara, the company focuses on providing a broad spectrum of therapeutic solutions.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical formulations across human and veterinary health segments. It operates as a B2B and B2C manufacturer, leveraging its production facilities to serve domestic and potentially international markets.
- Founded:1992
Growth Outlook
Growth is expected to be driven by the expansion of its pharmaceutical product portfolio and the increasing demand for specialised formulations like anti-retrovirals. The company continues to leverage its established manufacturing infrastructure to capture market share in the competitive Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The company faces stringent quality control and manufacturing standards imposed by health authorities, which could impact operations if non-compliance occurs.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can significantly affect profit margins.
- Market Competition. The pharmaceutical sector is highly fragmented and competitive, necessitating continuous investment in product development and cost efficiency.
- Pricing Controls. Government-mandated price caps on essential medicines may limit the company's ability to pass on cost increases to consumers.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Bharat Parenter. and 5,000+ companies — free.
Key Metrics
REVENUE
₹345 Cr
TTM · consolidated
NET PROFIT
₹27 Cr
TTM · consolidated
EPS
₹41.14
TTM · consolidated
RETURN ON EQUITY
8.3%
TTM · consolidated
P/E
33.0x
Q4 FY26 · consolidated
EV/EBITDA
14.7x
Q4 FY26 · consolidated
EBITDA MARGIN
21.2%
TTM · consolidated
NET PROFIT MARGIN
8.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26